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Diagnostic testingWe evaluated the limits of detection of 3 rapid inﬂuenza diagnostic tests—BD VeritorTM System for Flu A+B,
Binax NOW® Inﬂuenza A+B, and QuickVue® Inﬂuenza—for inﬂuenza strains circulating in 2010–2012. Limits
of detection varied by inﬂuenza strain, with VeritorTM Flu A+B test showing the lowest limit of detection
for all strains.BD Diagnostics (Sparks, MD,
+1-336-716-7100.
hling).
-NC-ND license.© 2013 Elsevier Inc. Open access under CC BY-NC-ND license.Treatment of inﬂuenza with neuraminidase inhibitor drugs should
be initiated early in the course of disease (Cofﬁn et al., 2011; Fiore
et al., 2011; Heinonen et al., 2010; Hernan and Lipsitch, 2011; Kaiser
et al., 2003; Treanor et al., 2000; Winther et al., 2010) but is
underutilized (Fiore et al., 2011; Louie et al., 2012). Timely diagnosis
of inﬂuenza is challenging (Hoeven et al., 2007; Talbot and Falsey,
2010), and conﬁrmation of inﬂuenza infection by rapid inﬂuenza
detection test can be helpful (http://www.cdc.gov/ﬂu/professionals/
diagnosis/clinician_guidance_ridt.htm). Rapid inﬂuenza detection
tests can limit unnecessary diagnostic workup, improve diagnostic
accuracy, and facilitate diagnosis and treatment early in the course of
disease (Abanses et al., 2006; Bonner et al., 2003; Garg et al., 2012;
Nitsch-Osuch et al., 2013; Noyola et al., 2000; Petrozzino et al., 2010;
Poehling et al., 2006; Sharma et al., 2002; Zakria, 2010).
Historically, most rapid inﬂuenza detection tests performed in
physicians' ofﬁces have 50–70% sensitivity and N90% speciﬁcity
compared to viral culture and real-time reverse-transcription poly-
merase chain reaction (rRT-PCR) (Chartrand et al., 2012). Test
sensitivity improves in patients with higher viral nasopharyngeal
load such as children and varies depending on virus type and strain.
Consequently rapid tests have been used as screening tests with
negative test needing conﬁrmation by viral culture or RT-PCR to
obtain laboratory-conﬁrmed diagnosis (http://www.cdc.gov/ﬂu/
professionals/diagnosis/clinician_guidance_ridt.htm). Improvingrapid inﬂuenza detection test sensitivity could result in improved
patient outcomes and reduced costs from other diagnostic testing.
The BD Veritor™ System for Rapid Detection of Flu A+B (BD
Diagnostics, Sparks, MD, USA) differed from visual-read rapid
inﬂuenza detection tests in that it provided an instrument-based
objective digital readout. This instrument-based, Clinical Laboratory
Improvement Amendments (CLIA)–waived rapid inﬂuenza detection
test was hypothesized to be more sensitive than visual-read rapid
tests now in widespread use. This study evaluated the limit of
detection of 3 CLIA-waived rapid inﬂuenza detection tests for 3
inﬂuenza strains that circulated in 2010–2011 and/or 2011–2012.
This study compared the BD Veritor™ Flu A+B test with 2 visual-
read tests, Binax NOW® Inﬂuenza A+B (Alere Scarborough, Scarbor-
ough, ME, USA) and QuickVue® Inﬂuenza Test (Quidel Corporation,
San Diego, CA, USA). Inﬂuenza strains that circulated in 2010–2012
and starting stock dilutions were as follows: inﬂuenza H1N1 A/
California/7/2009 (3.2 × 107 tissue culture infectious dose of 50% per
milliliter [TCID50/mL]), seasonal inﬂuenza H3N2 A/Brisbane 10/2007
(4.6 × 107 TCID50/mL), and inﬂuenza B/Victoria/504/00 (4.6 × 107
TCID50/mL). TCID50 was determined using standard methods (Reed
and Muench, 1938). Dilutions were performed using Universal
Transport Medium (Copan Diagnostics, Murietta, CA, USA).
Two-fold serial dilutions of each viral strain were prepared and
tested in triplicate using each rapid inﬂuenza detection test listed above.
A single study team member performed all rapid inﬂuenza detection
tests following the manufacturer's instructions and using controls from
each test kit. This test operator is experienced in performance of clinical
laboratory testing but is not a medical technologist. Serial 2-fold
dilutions with 20 μL each were prepared in de-identiﬁed tubes by one
study teammember. These de-identiﬁed sampleswere presented to the
Table 1
Triplicate results of inﬂuenza limit of detection analysis for 3 rapid inﬂuenza detection tests.
H1N1-A/California/
7/2009
Virus concentration 3.2 × 107 1.6 × 107 8.0 × 106 4.0 × 106 2.0 × 106 1.0 × 106 5.0 × 105 2.5 × 105 1.25 × 105
BD Veritor + + + + + + + + −
+ + + + + + + + −
+ + + + + + + + −
Binax + + + − ND ND ND ND ND
+ + + − ND ND ND ND ND
+ + + − ND ND ND ND ND
Quick-Vue + + + + − ND ND ND ND
+ + + + − ND ND ND ND
+ + + + − ND ND ND ND
H3N2-A/Brisbane/
10/2007
Virus concentration 4.6 × 107 2.3 × 107 1.2 × 107 5.8 × 106 2.9 × 106 1.4 × 106 7.2 × 105 3.6 × 105 1.3 × 105
BD Veritor + + + + + + + − ND
+ + + + + + + − ND
+ + + + + + + − ND
Binax + + + − ND ND ND ND ND
+ + + − ND ND ND ND ND
+ + + − ND ND ND ND ND
Quick-Vue + + + + + − ND ND ND
+ + + + + − ND ND ND
+ + + + + − ND ND ND
B-B/Victoria/504/00 Virus concentration 4.6 × 107 2.3 × 107 1.2 × 107 5.8 × 106 2.9 × 106 1.4 × 106 7.2 × 105 3.6 × 105 1.3 × 105
BD Veritor + + + + + + + − ND
+ + + + + + + − ND
+ + + + + + + − ND
Binax + + + + − ND ND ND ND
+ + + + − ND ND ND ND
+ + + + − ND ND ND ND
Quick-Vue + + + + + + − ND ND
+ + + + + + − ND ND
+ + + + + + − ND ND
Inﬂuenza virus concentration is expressed in TCID50/mL. Results are described as positive (+), negative (−), or not done (ND).
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negative tests in triplicate were reached. The test operator was blinded
to virus strain and concentration.
For each inﬂuenza strain and dilution, we performed the Centers
for Disease Control and Prevention (CDC) rRT-PCR protocol for
detection and characterization of inﬂuenza to ensure that all tested
samples contained expected inﬂuenza strains at detectable concen-
trations. Aliquots of 20 μL of each inﬂuenza dilution were put into lysis
buffer (AVL buffer, Qiagen, Valencia, CA, USA) for RNA extraction and
archived at −80 °C. Viral RNA from each aliquot was extracted with
the Qiagen QIAamp Viral RNAmini spin kit. rRT-PCRwas performed to
detect inﬂuenza A and B (positive crossing threshold of b40 cycles)
using the protocols and probe and primer sequences provided by the
CDC (Virus Surveillance and Diagnostics Branch, Inﬂuenza Division,
CDC). Fluorogenic probes and primers were synthesized to CDC
speciﬁcations by Biosearch Technologies, Novato, CA, USA.
All rapid inﬂuenza detection tests performed in triplicate were
concordant (either all positive or all negative) for each strain dilution
(Table 1). The BD Veritor™ Flu A+B test was 8- to 32-fold more
sensitive than the Binax NOW® Inﬂuenza A+B test and 2- to 16-fold
more sensitive than the QuickVue® Inﬂuenza Test for detection of the
study inﬂuenza strains. For all strains evaluated, the BD Veritor™ Flu A
+B test detected the lowest amount of inﬂuenza virus detectable by
these 3 rapid inﬂuenza detection tests. The rRT-PCR results were
positive for each inﬂuenza strain at the lowest concentration detected
by the rapid inﬂuenza detection tests, conﬁrming the presence of the
expected inﬂuenza type.
All 3 rapid inﬂuenza detection tests yielded concordant triplicate
results at the limit of detection with various strains, by a study team
operator blinded to sample strain and concentration. Under these
experimental conditions, a 2-fold difference in virus concentration
was sufﬁcient to establish a sharp detection cutoff for each rapid
inﬂuenza detection test. The high level of test performance precision
seen in this study partly reﬂects the consistent nature that samples
were prepared in the laboratory to exact concentration.This study has important limitations. This study does not directly
measure the performance of these rapid inﬂuenza detection tests on
patient samples and does not directly compare test sensitivity. This
study compares limits of detection in experiments that eliminate test
performance variability that occurs with sample collection and
preparation in the clinic setting. We expect that sample collection
and preparation steps equivalently impact the clinical performance
for different rapid inﬂuenza detection tests, but that was not tested in
this study. Additionally, virus dilutions were done in universal
transportmedia; test performancemight differ for samples containing
other substances found in nasopharyngeal specimens. We expect, but
have not proven, that a lower limit of detection will correspond to a
higher rapid inﬂuenza detection test sensitivity and superior test
performance in the clinical setting.
In summary, the limit of detection for each rapid inﬂuenza
detection test varied by inﬂuenza strain. The BD Veritor™ System
for Rapid Detection of Flu A+B had the lowest limit of detection for all
3 inﬂuenza strains, which was at least 2-fold and 8-fold lower than
those of QuickVue® Inﬂuenza Test and Binax NOW® Inﬂuenza A+B
Test, respectively. A lower detection limit and an objective read by the
BD Veritor™ System Flu A+B test may potentially impact clinical
sensitivity, facilitate accurate inﬂuenza diagnosis, and foster effective
antiviral use.
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